NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Tetiana Lapikova-Bryhinska and Simon Kraler on the Role of JCAD in Post-ACS Adverse Events Prediction
Tetiana Lapikova-Bryhinska/ResearchGate; Simon Kraler/LinkedIn
Dec 30, 2025, 12:29

Tetiana Lapikova-Bryhinska and Simon Kraler on the Role of JCAD in Post-ACS Adverse Events Prediction

Tetiana Lapikova-Bryhinska, Molecular Biology Researcher at UZH, reposted from Simon Kraler on LinkedIn:

”Exciting News!

I am honored to have been a co-author on our recently published study in the European Heart Journal, which explores the role of JCAD in predicting major adverse cardiovascular events following acute coronary syndrome (ACS).

A big thank you to Simon Kraler, Thomas F. Lรผscher, Giovanni G Camici, Alexander Akhmedov, and other colleagues for their collaboration and support throughout this important research.

Iโ€™m excited to share our findings and look forward to future advancements in cardiology, as well as the potential of JCAD as a therapeutic target.

This publication, released just in time for Christmas, feels like a wonderful gift as we enter the New Year!

Read the full paper here”

Quoting Simon Kraler‘s post:

”Residual risk: is it time to move ๐›๐ž๐ฒ๐จ๐ง๐ ๐‹๐ƒ๐‹-๐œ ๐š๐ง๐ ๐ข๐ง๐Ÿ๐ฅ๐š๐ฆ๐ฆ๐š๐ญ๐ข๐จ๐ง?

Despite guideline-directed lipid lowering and anti-inflammatory therapy, patients with a recent ACS remain at ๐ฏ๐ž๐ซ๐ฒ ๐ก๐ข๐ ๐ก ๐ข๐ฌ๐œ๐ก๐š๐ž๐ฆ๐ข๐œ ๐ซ๐ข๐ฌ๐ค.

Based on GWAS and mechanistic data, we hypothesized that JCAD (‘๐‰unctional Protein Associated with ๐‚oronary ๐€rtery ๐ƒisease’) on chromosome 10 might represent the missing link.

In our newly published European Heart Journal study, JCAD independently predicted 1-๐ฒ๐ž๐š๐ซ ๐Œ๐€๐‚๐„ in patients with residual lipid risk, inflammatory risk, or both – notably ๐ข๐ง๐๐ž๐ฉ๐ž๐ง๐๐ž๐ง๐ญ ๐จ๐Ÿ ๐‹๐ƒ๐‹-๐œ ๐š๐ง๐ ๐ก๐ฌ-๐‚๐‘๐.

High JCAD equals impaired ๐ž๐ง๐๐จ๐ ๐ž๐ง๐จ๐ฎ๐ฌ ๐Ÿ๐ข๐›๐ซ๐ข๐ง๐จ๐ฅ๐ฒ๐ฌ๐ข๐ฌ and high MACE risk, with similar results obtained during external validation.

JCAD may represent a ๐ง๐จ๐ฏ๐ž๐ฅ ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐ญ๐š๐ซ๐ ๐ž๐ญ to address residual risk after a recent ACS.

Full paper.

Special thanks to the colleagues and friends at University of Genoa, King’s College London, University of Zurich, CHUV | Lausanne university hospital, Universitรคtsspital Zรผrich, HUG – Hopitaux Universitaires de Genรจve and Insel Gruppe.

Thank you Thomas F. Lรผscher, Luca Liberale, Giovanni G Camici, Diana Gorog Lorenz Rรคber, Davide Di Vece, Yifan Wang, Francesco Bruno and all!”

Read the full article here.

Article: The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk

Authors: Simon Kraler , Luca Liberale , Amedeo Tirandi , Margherita Moriero , Yifan Wang , Mohamed Farag , Federico Carbone , Maria B Bertolotto , Valentina Pusterla , Davide Ramoni , Stefano Ministrini , Yustina M Puspitasari , Francesco Bruno , Lorenz Rรคber , Davide Di Vece , Christian Templin , Olivier Muller , Franรงois Mach , Filippo Crea , Giovanni G Camici , Tetiana Lapikova-Bryhinska , Alexander Akhmedov , Arnold von Eckardstein , Diana A Gorog , Fabrizio Montecucco , Thomas F Lรผscher

Tetiana Lapikova-Bryhinska and Simon Kraler on the Role of JCAD in Post-ACS Adverse Events Prediction

Stay updated on all scientific advances with Hemostasis Today.

ACS European Heart Journal Health Hematology Hemostasis Hemostasis Today JCAD LDL Medicine Tetiana Lapikova-Bryhinska thrombosis
NewsFeed